Astria Therapeutics Statistics Share Statistics Astria Therapeutics has 56.43M
shares outstanding. The number of shares has increased by 0.02%
in one year.
Shares Outstanding 56.43M Shares Change (YoY) 0.02% Shares Change (QoQ) 0% Owned by Institutions (%) 89.8% Shares Floating 45.57M Failed to Deliver (FTD) Shares 190 FTD / Avg. Volume 0.05%
Short Selling Information The latest short interest is 3.09M, so 5.47% of the outstanding
shares have been sold short.
Short Interest 3.09M Short % of Shares Out 5.47% Short % of Float 6.89% Short Ratio (days to cover) 10.28
Valuation Ratios The PE ratio is -5.33 and the forward
PE ratio is -2.69.
Astria Therapeutics's PEG ratio is
0.17.
PE Ratio -5.33 Forward PE -2.69 PS Ratio 0 Forward PS 377 PB Ratio 1.57 P/FCF Ratio -6.16 PEG Ratio 0.17
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Astria Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 17.49,
with a Debt / Equity ratio of 0.02.
Current Ratio 17.49 Quick Ratio 17.49 Debt / Equity 0.02 Debt / EBITDA -0.06 Debt / FCF -0.07 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.21M Employee Count 78 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -31.56% in the
last 52 weeks. The beta is 0.48, so Astria Therapeutics's
price volatility has been higher than the market average.
Beta 0.48 52-Week Price Change -31.56% 50-Day Moving Average 6.04 200-Day Moving Average 7.11 Relative Strength Index (RSI) 47.13 Average Volume (20 Days) 386,227
Income Statement
Revenue n/a Gross Profit n/a Operating Income -111.56M Net Income -94.26M EBITDA -94.26M EBIT -94.26M Earnings Per Share (EPS) -1.67
Full Income Statement Balance Sheet The company has 59.82M in cash and 5.35M in
debt, giving a net cash position of 54.47M.
Cash & Cash Equivalents 59.82M Total Debt 5.35M Net Cash 54.47M Retained Earnings -674.79M Total Assets 310.39M Working Capital 285.54M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -81.21M
and capital expenditures -325K, giving a free cash flow of -81.54M.
Operating Cash Flow -81.21M Capital Expenditures -325K Free Cash Flow -81.54M FCF Per Share -1.45
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ATXS does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ATXS is $27,
which is 304.2% higher than the current price. The consensus rating is "Buy".
Price Target $27 Price Target Difference 304.2% Analyst Consensus Buy Analyst Count 6
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Aug 20, 2021. It was a
backward
split with a ratio of 1:6.
Last Split Date Aug 20, 2021 Split Type backward Split Ratio 1:6
Scores Altman Z-Score 6.67 Piotroski F-Score 1
